Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 107

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 4
Chunk 107
---
 milestone is met. The total number of shares subscribed by the shareholders under the Share Subscription & Shareholders
Agreement is around 2.7 million. After the two tranches of subscription, Aptorum, Accelerate Technologies and the Founding Scientists
are expected to control 71.23%, 14.25% and 9.53% of the share of Paths Diagnostics Pte. Limited respectively, with 4.99% of the shares
reserved for its employee share plan.

On December 30, 2020, Paths
Innovations Limited, one of the Company’s wholly owned subsidiaries, entered into an Evaluation Agreement with Illumina Inc (“ Illumina”).
Pursuant to the agreement, Paths Innovations Limited will evaluate the data and performance of Illumina’s sequencing technology
based on the workflow of PathsDxTest, a novel molecular-based rapid pathogen identification and detection diagnostics technology,
at Paths Innovations Limited’s Singapore based evaluation site.

In May 2023, our subsidiary,
Aptorum Therapeutics Limited (“ ATL”), a company incorporated under the laws of Grand Cayman Islands entered into a non-binding
Letter of Intent and Term Sheet (“ Term Sheet”) to merge (“ Transaction”) its 100% subsidiary, Paths Innovation
Limited and its underlying business (collectively “ PathsDx Group”) with Universal Sequencing Technology Corporation (“ UST”),
a San Diego and Boston based US company dedicated to the development and commercialization of advanced proprietary DNA sequencing technologies.
Paths Innovation Limited currently holds, through its majority owned subsidiary Paths Diagnostics Pte. Limited, the PathsDx technology
 - a liquid biopsy NGS based technology for the diagnostics of infectious diseases. As consideration of the transaction upon closing,
ATL will become a shareholder of the combined company. The transaction and other ancillary distributions, where relevant, remain subject
to, among other matters, the execution of a mutually agreeable definitive agreement, completion of due diligence and subject to several
conditions including, but not limited to, director and shareholder approvals.

Our Strategy

The Company will position
itself to catalyze the development and improvement of a broad range of novel and repurposed therapeutics and diagnostics across a wide
range of disease/therapeutic areas. Failure to achieve positive results in at least one of the programs for a Lead Project could have
a material adverse effect on the Company’s prospects and business.

To achieve this goal, we are
implementing the following strategies:

  Selectively expanding our portfolio with potential